Vancouver, Canada – April 30, 2025 – Onco-Innovations Limited (CSE: ONCO) (Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) (“Onco” or the “Company“) is pleased to announce that it has closed its previously-announced (see news release dated April 16, 2025) non-brokered private placement (the “Private Placement”) of 400,000 units of the Company (the “Units”) at a price of $1.50 per Unit, for aggregate gross proceeds of $600,000. Each Unit consists of one common share (each a “Share”) and one common share purchase warrant (each whole warrant, a “Warrant”), with each (whole) Warrant entitling the holder to purchase one Share at an exercise price of $1.60 for a period of thirty-six (36) months expiring April 30, 2028.

The proceeds from the Private Placement will be used for general corporate and working capital purposes, including in pursuit of the Company’s operational and research and development objectives.

The Company has also issued 4,000 Shares (“Administrative Shares”) at a deemed price of $1.50 per Administrative Share of the Company  to an arm’s-length third party, in consideration for administrative services rendered in connection with the Private Placement.

Pursuant to applicable securities laws, all securities issued under the Private Placement and the Administrative

Shares will be subject to a statutory hold period of four months and one day, expiring on August 31, 2025.

The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to prevent and cure cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco’s commitment to excellence and innovation drives it to develop advanced  therapies  that  improve  patient  outcomes  and  offer  hope  in  the  fight  against  cancer.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy” Chief Executive Officer

For more information, please contact: Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to use of proceeds of the Private Placement, as well as to the Company’s business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “potential”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include that the proceeds from the Private Placement may be used other than as currently contemplated, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.